Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy)...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C H W, Smit, Vincent T H B M, Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A, Feeney, Amanda, Verhoeven-Adema, Karen W, Putter, Hein, Creutzberg, Carien L
Формат: Artigo
Язык:Inglês
Опубликовано: Lancet Pub. Group 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5840256/
https://ncbi.nlm.nih.gov/pubmed/29449189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30079-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы